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Abstract
Background: About 10-20% of neonates with suspected or proven early onset sepsis (EOS) fail on the
empiric antibiotic regimen of ampicillin or penicillin and gentamicin. We aimed to identify clinical and
laboratory markers associated with empiric antibiotic treatment failure in neonates with suspected EOS.
Methods: Maternal and early neonatal characteristics predicting failure of empiric antibiotic treatment
were identified by univariate logistic regression analysis from a prospective database of 283 neonates
admitted to neonatal intensive care unit within 72 hours of life and requiring antibiotic therapy with
penicillin or ampicillin and gentamicin. Variables, identified as significant by univariate analysis, were
entered into stepwise multiple logistic regression (MLR) analysis and classification and regression tree
(CRT) analysis to develop a decision algorithm for clinical application. In order to ensure the earliest
possible timing separate analysis for 24 and 72 hours of age was performed.
Results: At 24 hours of age neonates with hypoglycaemia ≤ 2.55 mmol/L together with CRP values > 1.35
mg/L or those with BW ≤ 678 g had more than 30% likelihood of treatment failure. In normoglycaemic
neonates with higher BW the best predictors of treatment failure at 24 hours were GA ≤ 27 weeks and
among those, with higher GA, WBC ≤ 8.25 × 109 L-1 together with platelet count ≤ 143 × 109 L-1. The
algorithm allowed capture of 75% of treatment failure cases with a specificity of 89%. By 72 hours of age
minimum platelet count ≤ 94.5 × 109 L-1 with need for vasoactive treatment or leukopaenia ≤ 3.5 × 109 L-
1 or leukocytosis > 39.8 × 109 L-1 or blood glucose ≤ 1.65 mmol/L allowed capture of 81% of treatment
failure cases with the specificity of 88%. The performance of MLR and CRT models was similar, except for
higher specificity of the CRT at 72 h, compared to MLR analysis.
Conclusion: There is an identifiable group of neonates with high risk of EOS, likely to fail on conventional
antibiotic therapy.
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Background
The role of early adequate antibacterial (AB) therapy in
reducing mortality of serious infections in adult intensive
care setting has been well recognised [1] and has led to
implementation of broad spectrum agents as a primary
choice in high risk situations. In neonatal care the present
use of empirical antibiotics has not allowed similar
approach, as only about 2-4% of all neonates receiving it,
finally develop proven serious infections [2,3]. In addi-
tion, widespread use of broad spectrum agents carries the
potential hazard of increasing antimicrobial resistance
and probably even mortality [4-6]. However, in the era of
the escalating role of Gram-negative bacteria in neonatal
early onset sepsis (EOS) and spreading antibiotic resist-
ance among community acquired strains [2,7] immediate
implementation of broad spectrum coverage in a selected
population of neonates with high risk of treatment failure
might be justified. Neonatal sepsis is a complex disease
with variable clinical presentation and severity. The rou-
tine interpretation of clinical and laboratory parameters is
generally of little help in distinguishing between patients
infected with antibiotic resistant and susceptible microor-
ganisms. Furthermore blood cultures are often negative
and their results will be available after 24 h the earliest
[8,9]. To our best knowledge no study has identified clin-
ical and laboratory markers associated with AB treatment
failure in proven or suspected EOS.
Classification and regression tree (CRT) analysis has
gained increasing popularity as a method for clinical deci-
sion rule construction due to its proven ability of outcome
prediction [10] and relatively easy application of the
results in everyday clinical practice [11]. The analysis com-
bines the advantages of statistical approach (regression
analysis) and data mining techniques (decision tree) for
generation of easily interpretable rules for clinical deci-
sion making [12]. The aim of the present study was to
identify perinatal and early neonatal factors that could
predict failure of empiric AB regimen of ampicillin or pen-
icillin with gentamicin, in neonates with high suspicion
of EOS.
Methods
Study design and empirical antibiotic treatment
A post-hoc analysis of a prospective database of an open
label cluster-randomised study conducted in two third
level neonatal intensive care units (NICU) in Estonia from
August 2, 2006 to November 30, 2007 was performed.
The study aimed to compare the clinical efficacy of ampi-
cillin and gentamicin to that of penicillin G and gen-
tamicin in the empirical treatment of EOS. The details of
the study design have been described elsewhere [13]. As
no difference between the clinical efficacy of the empirical
antibiotic regimens was detected, the data of patients in
both study arms were pooled.
Patients
The study included all neonates admitted within the first
72 h of life, needing antibiotic treatment with ampicillin
or penicillin combined with gentamicin for suspected
EOS or due to risk factors of infection according to the
CDC criteria (e.g. maternal chorioamnionitis and/or
maternal risk factors of infection and/or preterm labour in
<35 weeks of gestation) [14]. The exclusion criteria were
prior administration of a different antibiotic regimen for
more than 24 h, transfer to another unit within the first 24
h or presence of suspected or proven meningitis, necrotiz-
ing enterocolitis (NEC), peritonitis or severe sepsis and
septic shock with isolation of microorganisms resistant to
the initial empiric regimen in maternal urinary tract or
birth canal or other situations where the treating physi-
cian considered a different antibiotic regimen necessary.
Data collection
The following maternal and perinatal characteristics were
registered: maternal age and parity; history of spontane-
ous and artificial abortions; history of a neonate with
group B streptococcal (GBS) disease; maternal chronic
diseases, with special attention to diabetes, autoimmune
diseases and malignancies; therapies used during preg-
nancy; drug and alcohol abuse; smoking; number of foe-
tuses; invasive procedures during pregnancy
(amniocentesis, foetal transfusions, cervical cerclage);
date of maternal bacterial infections during pregnancy,
including pathogens isolated from urinary tract and birth
canal; type and time of AB treatment during pregnancy
and delivery; premature rupture of membranes (PROM)
for more than 18 h; prenatal glucocorticoid prophylaxis,
divided as partial (delivery occurred in less than 24 h after
the administration of the first dose) or full course (deliv-
ery occurred more than 24 h after the administration of
the first dose); mode of delivery, including reasons for
caesarean section (CS). The latter were further grouped as
foetal if signs of acute foetal distress or medically indi-
cated early CS for signs of foetal compromise were present
or maternal in all other reasons [15,16].
Early neonatal parameters included demographic charac-
teristics and need of intensive care interventions within
the first 72 h of life as follows: birth weight (BW) and ges-
tational age (GA); first and fifth minute Apgar score; need
for respiratory support in the delivery room, age at intuba-
tion and surfactant administration, need and duration of
sustained respiratory support; age on admission to NICU,
time and type of initial and subsequent AB regimens, need
for vasoactive therapy within the first three days of life
with number of agents used; and intolerance of enteral
feeding, defined as less than 10% of total calories supplied
via the enteral route. If adequate enteral feeding was not
tolerated, neonates received parenteral nutrition from the
first day of life. Mean arterial blood pressure below theBMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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value of GA in weeks and/or signs of inadequate tissue
perfusion reflected by metabolic acidosis, elevated serum
lactate level served as an indication for vasoactive therapy.
The following laboratory values were registered at least
once a day: total blood count (TBC) including white
blood cell count (WBC), differential and ratio of imma-
ture to total neutrophil count (I/T ratio), C-reactive pro-
tein (CRP); serum glucose and total bilirubin. The values
of serum albumin, creatinine, urea and liver function tests
(LFT) were registered for Days 2-3 only, as the Day 1 val-
ues were considered to reflect the condition of the mother
rather than that of the neonate.
The diagnosis of EOS was defined as sepsis occurring
within the first 72 h of life [2] and was based on at least
two clinical (hyper- or hypothermia, apnea or bradycardia
spells, increased oxygen requirement, feeding intolerance,
abdominal distension, lethargy and hypotonia, hypoten-
sion, skin and subcutaneous lesions such as petechial
rash, abscesses, sclerema) and two laboratory criteria
(WBC <5000 or >20,000 × 109 cells/L; I/T ratio > 0.2;
platelet count <100,000 × 109/L; CRP >10 mg/L) [17].
Proven sepsis was diagnosed, when in addition to the clin-
ical and laboratory signs of sepsis a true pathogen (except
coagulase-negative staphylococci (CoNS) that had to be
isolated from at least two different specimens or with only
one positive culture adequate antibiotic treatment had to
be given for more than 72 hours) was isolated from a nor-
mally sterile body fluid [18], all other cases were termed
clinical sepsis. Autopsy with histological investigations to
look for evidence of inflammation was conducted in all
deaths.
Failure of empiric antibiotic therapy
The study protocol pre-specified the following criteria for
the change of initial (in first 72 hours) antibiotics: (1) sus-
picion of meningitis or abdominal infection/NEC; (2)
isolation of bacteria resistant to the empiric antibiotic reg-
imen from maternal urinary tract/birth canal of a neonate
with signs and symptoms of sepsis; (3) isolation of bacte-
ria resistant to the empiric antibiotic regimen from a
neonate with signs and symptoms of sepsis; (4) no
improvement or deterioration of clinical findings; (5) sus-
picion of nosocomial infection and (6) other situations
where the treating physician considered change of antibi-
otic regimen necessary [13]. In the comparison of ampicil-
lin plus gentamicin vs penicillin plus gentamicin in the
empiric treatment of EOS, all cases where AB treatment
was changed within 72 h and all early neonatal deaths
were considered treatment failures. For the purposes of
this analysis a further review was conducted by two of us
(TM and IL) taking into account final clinical and autopsy
data. Only cases with clear evidence of infection were
included and they formed a group of empiric antibiotic
therapy failure, divided as follows: (1) isolation of EOS
etiologic pathogen(s), resistant to initial therapy, from
normally sterile body fluids; (2) diagnosis of clinical EOS
and death with autopsy confirming congenital infection
(polymorphonuclear infiltration of multiple tissues with
or without bacteria on Gram-stain and microbiological
cultures positive for a known neonatal pathogen) or clin-
ical EOS and major sepsis-related complication (i.e. intra-
ventricular haemorrhage grade III-IV) within the first
week of life; (3) change of empirical AB therapy within 72
h due to deterioration of EOS with the new regimen con-
tinued for more than 72 h.
Statistical analysis
Statistical analysis was performed using statistical soft-
ware R 2.7.2 http://www.r-project.org/. To identify predic-
tors of treatment failure from maternal and neonatal
characteristics and laboratory tests univariate logistic
regression analysis was applied. If both high and low lev-
els of a laboratory test would be considered abnormal (i.e.
WBC, blood glucose), generally accepted normal limits
were applied to test the possible predictive potential of a
given parameter. For laboratory values indicative of sepsis
the following cut-off levels were applied: WBC <5000 or
>20,000 × 109  cells/L; I/T ratio > 0.2; platelet count
<100,000 × 109/L; CRP >10 mg/L [17]. For blood glucose
values between 3.0 and 5.5 mmol/L were used as normal
limits [19].
In order to find the best combination of predictors for
antibiotic treatment failure, all parameters significant at a
p value of ≤ 0.05 in univariate logistic regression analysis
were entered into multiple logistic regression (MLR) anal-
ysis with backward stepwise removal of parameters in
order of insignificance. CRT analysis was performed with
the function rpart of package R [20]. Recursive partition-
ing with binary cut of entered variables was used for the
decision tree development and the best separator of treat-
ment failure and success was chosen for tree root. The
same process was repeated until the best discrimination
between treatment success and failure was achieved or
until the minimum allowed number of seven patients per
node was met. For tree pruning the k-fold cross-validation
was applied. Surrogate splitting was used to handle miss-
ing values. To ensure the earliest possible timing of deci-
sions separate MLR and CRT analysis of data available by
24 and 72 h of age was performed. For laboratory tests the
highest and lowest values within 72 h were incorporated
as continuous variables to allow generation of splitting
values with maximum information gain. Specificity, sen-
sitivity, positive and negative predictive values were calcu-
lated for each prediction.
The study was approved by the Ethics Committee of the
University of Tartu.BMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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Results
The study included 283 patients; 142 were treated with
ampicillin and 141 with penicillin, both in combination
with gentamicin. Another 29 neonates were considered to
require antibiotic therapy, different from the study regi-
men, on admission - 18 received preoperative antibacte-
rial prophylaxis with cefazolin; four had suspected NEC
and/or peritonitis and received metronidazole, ampicil-
lin-sulbactam and/or piperacillin-tazobactam; three
received cefotaxime for suspected meningitis and one for
severe renal failure; one neonate received fluconazole
treatment for candidiasis. Of the study population 79%
were born in the same regional centres, participating in
the study, with transfer times ranging from 10-20 min-
utes; the remaining 21% were out-born, transported by a
specialised neonatal transport team from county hospi-
tals. Basic demographic and clinical characteristics of the
study population are shown in Table 1. Neonates who
failed on initial empiric AB treatment had significantly
lower GA and BW, were more often born to mothers with
chorioamnionitis, had lower first and fifth minute Apgar
scores, required more often surfactant therapy, were more
likely to have proven EOS and to die within 7 days than
those with AB treatment success. A total of 14 cases of EOS
were bacteriologically proven: Streptococcus agalactiae - 4;
Staphylococcus epidermidis - 3, Staphylococcus haemolyticus -
1, Escherichia coli - 2, Enterobacter cloacae - 2, Haemophilus
influenzae - 1, Candida albicans - 1. In all 3 cases of S. epi-
dermidis sepsis the diagnosis was based on at least 2 posi-
tive blood cultures not more than 72 h apart. The only
case of S. haemolyticus EOS was based on a single positive
blood culture in a neonate with clinical and laboratory
signs of sepsis (CRP 151 mg/l, I/T ratio 0.65); unfortu-
nately no further blood cultures were taken from the baby
within the next 72 h. Twenty four neonates died within
the first week of life (14 of infectious and 10 of non-infec-
tious causes); autopsy was performed in all cases. Among
the 10 deaths, not related to infection, six subjects had res-
piratory distress and died of respiratory failure or of com-
plications of prematurity; autopsy results and post-
mortem cultures were not suggestive of infection in any
case; four neonates had major congenital malformations:
severe pulmonary hypoplasia, complex cardiac malforma-
tion, oesophageal atresia with tracheo-oesophageal fistula
(died of mediastinitis after surgical repair) and lethal
dwarfism.
Failure of empiric antibiotic therapy
A total of 32 neonates fulfilled the criteria of AB treatment
failure, 21 of whom had culture and/or histologically
proven sepsis (Table 2). Two of 10 resistant microorgan-
isms causing EOS (S. haemolyticus and Candida albicans)
were resistant to both and eight to one component of the
corresponding empiric antibiotic treatment (E. coli and E.
cloacae to ampicillin and 3 strains of S. epidermidis, E. coli,
E. cloacae and H. influenza to penicillin; both E. coli and E.
cloacae strains were susceptible to gentamicin); AB therapy
was changed within 72 h in two cases. Among the 14 cases
of early neonatal death due to infection, four had culture
proven EOS and the remaining 10 had histological
changes suggestive of infection. Another eleven neonates
with the diagnosis of clinical EOS had AB treatment
changed within the first 72 h due to deteriorating clinical
condition (n = 4) or suspected meningitis (n = 7); with the
new treatment regimen started at a median age of 46
(range 19-62) hours. Among the seven neonates, who
were assigned to a new antibiotic regimen for suspected
meningitis, in one the diagnosis was confirmed by cere-
brospinal fluid laboratory results (bacterial aetiology was
not identified) and the other six had the diagnosis of clin-
ical EOS. None of these infants died, but in all seven cases
new antibiotic regimen was continued for a full course of
10-14 days and all these cases were included into treat-
ment failure group based on the criterion III (Table 2).
Altogether in nine cases antibiotic regimen was changed
because of deteriorating clinical condition; four died of
clinical EOS, confirmed by autopsy (treatment failure cri-
terion II in Table 2) and one of EOS due to Candida albi-
cans, isolated from blood (treatment failure criterion I in
Table 2). The remaining four neonates had the final diag-
nosis of clinical EOS and recovered after a 7-10 day course
of the new AB regimen (treatment failure criterion III in
Table 2).
Univariate and multiple logistic regression and 
classification and regression tree analysis
Univariate logistic regression analysis identified a total of
21 factors (4 maternal, 6 neonatal and 14 laboratory
parameters) as predictors of treatment failure (Table 3).
Complete set of data for MLR was available for 201/251
(80%) treatment success and 31/32 (97%) treatment fail-
ure cases at 24 hours and for 252 (89%; 222 cases of treat-
ment success and 30 cases of treatment failure) at 72
hours; the factors predicting failure are presented in Table
4. The four parameters (need for vasoactive treatment,
WBC <5000 or >20000 per mm3, I/T ratio >0.2 and plate-
let count) identified by MLR at 24 hours predicted treat-
ment failure and success correctly in 19/31 (sensitivity
61%) and 180/201 cases (specificity 90%), respectively
(Table 5). Among predictors of treatment failure at 24
hours only need for vasoactive treatment and platelet
count, remained significant also at 72 hours (Table 4).
The 72 hour model predicted treatment failure and suc-
cess correctly in 24/30 (sensitivity 80%) and 173/222
cases (specificity 78%), respectively.
The CRT model, as created through recursive partitioning
of parameters available by 24 h of age and the distribution
of patients through the model, is shown in Figure 1. The
principal discriminator was hypoglycaemia ≤ 2.55 mmol/BMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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L which was followed by CRP values > 1.35 mg/L in
infants with hypoglycaemia and by BW ≤ 678 g in those
without. Further partitioning was based on GA ≤ 27 weeks
or WBC ≤ 8.25 × 109 L-1 together with platelet count ≤
143 × 109 L-1. Applying antibiotic failure probability of
0.3 as a cut-off limit the algorithm allowed capture of 75%
of treatment failure cases (24/32; 95% CI 56-87%) with a
specificity of 89% (223/251; 95% CI 84-92%). The model
using data available by 72 h of age together with the dis-
tribution of patients is shown in Figure 2. Compared to
data available by 24 h, platelet count ≤ 94.5 × 109 L-1 was
identified as the principal discriminator, followed by the
need for vasoactive treatment or WBC < 3.5 × 109 L-1. Fur-
ther discriminators identified by the software and the cor-
Table 1: Demographic and main clinical characteristics
AB success
N = 251
AB failure
N = 32
OR (95% CI) or
p-value
Gestational age (weeks) - mean (SD) 31.7 (5.1) 28.8 (4.4) 0.0034
>36 weeks - n (%) 55 (21.9) 2 (6.3) 0.24 (0.06-1.03)
<28 weeks - n (%) 61 (24.3) 14 (43.8) 2.42 (1.14-5.16)
<26 weeks - n (%) 35 (13.9) 10 (31.3) 2.81 (1.23-6.42)
Birthweight (g) - mean (SD) 1913 (1086) 1350 (978) 0.0065
<1501 g - n (%) 122 (48.6) 23 (71.9) 2.70 (1.20-6.07)
<1001 g - n (%) 59 (23.5) 16 (50.0) 3.25 (1.53-6.90)
<751 g - n (%) 23 (9.2) 11 (34.4) 5.19 (2.23-12.10)
M/F sex - n 143/108 20/12 1.26 (0.59-2.69)
Apgar score at 1 min - mean (SD) 5.3 (2.1) 4.3 (1.9) 0.0114
Apgar score at 5 min - mean (SD) 6.5 (1.5) 5.9 (1.5) 0.0422
Ventilated - n (%) 187 (74.5) 28 (87.5) 2.40 (0.81-7.09)
Surfactant - n (%) 141 (56.2) 28 (87.5) 5.46 (1.86-16.03)
Cesarean section - n (%) 142 (56.6) 15 (46.9) 0.68 (0.32-1.42)
Multiple pregnancies - n (%) 50 (19.9) 7 (21.9) 1.13 (0.46-2.75)
Chorioamnionitis - n (%) 40 (15.9) 11 (34.4) 2.76 (1.24-6.17)
PROM >18 h - n (%) 46 (18.3) 7 (21.9) 1.25 (0.51-3.06)
Prenatal glycocorticoids (full course) - n (%) 106 (42.2) 8 (25.0) 0.46 (0.20-1.05)
AB therapy during pregnancy 61 (24.3) 4 (12.5) 0.45 (0.15-1.32)
AB therapy during delivery 91 (36.3) 6 (18.8) 0.41 (0.16-1.02)
Proven EOS - n (%) 4 (1.6) 10 (31.3) 28.07 (8.13-96.88)
Early neonatal mortality - n (%) 10 (4.0) 14 (43.8) 18.74 (7.31-48.10)
OR - odds ratio; 95% CI - 95% confidence interval; PROM - premature rupture of membranes; EOS - early onset neonatal sepsis; AB - antibioticBMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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responding cut-off values were WBC > 39.8 × 109 L-1 and
blood glucose ≤ 1.65 mmol/l, respectively. Incorporating
72 h data to CRT model lowered the cut-off probability of
treatment failure to 0.27 and the performance of the algo-
rithm improved to a sensitivity of 81% (26/32; 95% CI
63-92%) and a specificity of 88% (221/251; 95% CI 83-
91%). A total of 36 cases were misclassified (6 AB failure
and 30 success cases), resulting in an overall accuracy of
87%.
The comparative performance of MLR and CRT models is
shown in Table 5. Both statistical approaches achieved
high negative predictive values at 24 and 72 h of life; how-
ever the positive predictive value (PPV) remained below
50% in all predictions. At 72 h the CRT model achieved
higher specificity than MLR analysis.
Discussion
To our knowledge this is the first study attempting to
identify clinical characteristics, predictive of empirical
antibiotic treatment failure in neonates with high suspi-
cion of EOS. We suggest two clinical decision algorithms
that allow prediction of AB treatment failure with a sensi-
tivity of 75-81% and a specificity of 88-89% by 24 and 72
h of age, respectively. Using CRT analysis we have identi-
fied cut-off limits for early clinical parameters of uncon-
trolled sepsis, like WBC, blood glucose and platelet count,
allowing, when combined with GA and BW data, capture
of 75% of treatment failure cases with a specificity of 89%
within 24 h.
CRT analysis was chosen, as more traditional methods,
like MLR are often cumbersome or of limited utility for
bedside application [21,22]. The decision algorithms
resulting from CRT analysis with the graphical presenta-
tion, on the contrary, are easy to interpret and apply in
clinical practice. This analysis is inherently non-paramet-
ric, so that no assumptions are made regarding the under-
lying distribution of variables and thus categorical as well
as continuous parameters can be used. In CRT analysis the
data are allowed to determine which clinical variables (as
well as the corresponding cut-offs for continuous varia-
bles) are applied [23]. The order and use of variables are
derived by the software without any bias other than the
choice of potential predictors. In order to avoid any inves-
tigator induced bias all maternal, early neonatal and lab-
oratory parameters identified by univariate regression
analysis as significant predictors of treatment failure, were
included.
The performance of the MLR models as well as the CRT
algorithms is similar to those, described for identification
of blood stream infections in febrile patients [23,24].
However, compared with MLR, CRT analysis achieved
higher sensitivity in identification of patients who fail on
initial AB regimen at 24 hours and higher specificity by 72
hours of age, even with the relatively low cut-off probabil-
ity of treatment failure (0.27-0.30). The latter ensured
higher sensitivity, as inadequate AB therapy carries high
risk for the patient. Nevertheless, a high negative predic-
tive value was preserved for both analyses, which is of
equal importance in order to avoid unnecessary AB expo-
sure. In consistency with the time course of disease the
model used slightly different choice of parameters and
cut-off values depending on the evaluated time point; not
surprisingly a more profound deviation from normal val-
ues was detected by 72 h, compared to 24 h of age.
Although all parameters identified for the decision algo-
rithms have been used as diagnostic markers of EOS ear-
lier [25] this analysis allowed to identify cut-off values for
AB treatment failure, as determined by the data, at well
Table 2: Distribution of patients with empiric antibiotic treatment failure
Failure of early empirical AB regimen - N (% of all study patients) 32 (11.6)
I Proven EOS with etiologic pathogen(s) resistant to initial empirical AB therapy - n (% of treatment failure) 10 (31.3)
died within 7 days 4
II clinical EOS and death (with autopsy confirming the diagnosis of congenital infection) and/or major sepsis-related complication 
(IVH III-IV) within the first week of life - n (% of treatment failure)
11a (34.4)
died within 7 days 10
III clinical EOS and change of initial empirical AB therapy within 72 h with new regimen continued for more than 72 h - n 
(% of treatment failure)
11 (34.4)
All cases are represented once - in the "highest" applicable category, i.e. a neonate with culture positive sepsis with a pathogen, resistant to empiric 
regimen is included only in proven EOS category, independent of whether he died within 7 days or not. a includes an ELBW neonate with clinical 
EOS and IVH IV by the third day of life who died on Day 8, autopsy confirmed the diagnosis of EOS. AB - antibiotic; EOS - early onset sepsis; IVH - 
intraventricular haemorrhageBMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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Table 3: Significant predictors of empiric antibiotic failure: results of univariate logistic regression analysis
OR (95% CI) p-value
Maternal and perinatal characteristics
Maternal chorioamnionitis (yes vs. no) 2.76 (1.24-6.17) 0.0132
Maternal smoking during pregnancy (yes vs. no) 3.13 (1.05-9.38) 0.041
Isolation of a pathogen from maternal urinary tract; birth canal or placenta during delivery 6.39 (1.36-29.97) 0.0187
Neonatal characteristics
1st minute Apgar score (per 1 point increase) 0.79 (0.66-0.95) 0.0124
Birthweight (per 100 g increase) 0.94 (0.89-0.98) 0.008
Gestational age (per week increase) 0.88 (0.81-0.96) 0.004
Age on admission to ICU (per hour increase) 0.84 (0.70-0.99) 0.0411
Number of vasoactive drugs (per 1 additional drug) 2.50 (1.76-3.54) 0.000
Intolerance of enteral feeds within 3 days 2.64 (1.17-5.92) 0.0188
Laboratory characteristics
WBC <5000 or >20000 per mm3 on Day 1 3.42 (1.61-9.47) 0.0014
WBC <5000 or >20000 per mm3 on Day 2-3 2.84 (1.33-6.10) 0.0072
I/T ratio >0.2 on Day 1 3.90 (1.61-9.47) 0.0026
I/T ratio >0.2 on Day 2-3 4.25 (1.55-11.62) 0.0048
Platelet count on Day 1 (per 10,000 mm-3 increase) 0.89 (0.83-0.95) 0.0003
Platelet count on Day 2-3 (per 10,000 mm-3 increase) 0.86 (0.81-0.92) 0.0000
Haemoglobin on Day 2-3 (per 10 g/L increase) 0.72 (0.60-0.86) 0.0002
C-reactive protein > 10 mg/l on Day 1 3.34 (1.39-8.01) 0.007
C-reactive protein > 10 mg/l on Day 2-3 2.53 (1.17-5.45) 0.0179
Blood glucose < 3.0 mmol/l or >5.5 mmol/l on Day 1 4.28 (1.45-12.64) 0.0084
Blood glucose < 3.0 mmol/l or >5.5 mmol/l on Day 2-3 3.72 (1.55-8.97) 0.0034
Urea on Day 2-3 (per 1 mmol/L increase) 1.08 (1.00-1.16) 0.0411
Serum albumin on Day 2-3 (per 1 g/L increase) 0.82 (0.76-0.90) 0.0000
Serum AST on Day 2-3 (per 1 IU/L increase) 1.00 (1.00-1.00) 0.0231
OR - odds ratio; 95% CI - 95% confidence interval; ICU - intensive care unit; WBC - white blood cell count; I/T ratio - immature to total neutrophil 
ratio; AST - aspartate aminotransferaseBMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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defined time points. The fact that all included parameters
are readily available in most NICUs enhances the clinical
applicability of the decision tree considerably. Hypogly-
caemia has been suggested as a predictor of adverse out-
come in neonatal infections [26]. Still, we have identified
different cut-off levels for blood glucose at 24 and 72 h of
age, with lower levels applied with advancing age. The 72
h blood glucose level of less than 1.65 mmol/l identified
in this study is somewhat lower compared to 2.4 mmol/l
shown to be associated with adverse outcome of neonatal
septic shock in a recent study by Kermorvant [26]. Similar
to Bachur and co-authors who used CRT analysis in febrile
infants for identification of serious bacterial infections
[23] we found that not neutrophil count or I/T ratio but
the total WBC, with the cut-off values of <8.25 × 109 L-1 at
24 h and <3.5 × 109 L-1 or >39.8 × 109 L-1 at 72 h of age,
has the best discriminative power in prediction of AB
treatment failure in neonates with high risk of EOS. In
concordance with the results of Kermorvant and co-
authors who found that thrombocytopenia is associated
with adverse outcome in neonatal septic shock [26] our
results show that thrombocytopenia ≤ 94.5 × 109 L-1 has
excellent discriminative power in infants needing con-
comitant vasoactive support by 72 h of age, i.e. those in
shock. However, both are relatively late signs of sepsis. A
significantly higher platelet count of ≤ 143 × 109 L-1, when
present concomitantly with WBC <8.25 × 109 L-1 was
found to be predictive of treatment failure in suspected
EOS early in the course of disease, within 24 h of age. The
inclusion of low BW and GA in the 24 h model could be
expected as predominance of Gram-negative EOS has
been described in VLBW neonates [2,27].
We chose an approach focusing on failure of empiric AB
therapy, as there is a large body of data from adult inten-
sive care supporting the crucial role of adequate initial AB
therapy in sepsis outcomes [1]. In our study about 11% of
neonates with high risk of EOS failed on the presently
most widely used antibiotic regimen of ampicillin or pen-
icillin in combination with gentamicin, compared to 20%
reported for ampicillin plus gentamicin in a previous
study by Tessin et al [28]. According to our results in 65%
Table 4: Multiple logistic regression analysis of clinical and laboratory variables predicting failure of empiric antibiotic regimen at 24 
and 72 hours of age
OR (95% CI) p-value
24 hour model (n = 232)
Need for vasoactive treatment 2.83 (1.21-6.66) 0.0167
WBC <5000 or >20000 per mm3 on Day 1 2.51 (1.09-5.81) 0.0308
I/T ratio >0.2 on Day 1 2.79 (1.10-7.11) 0.0312
Platelet count on Day 1 (per 10,000 mm-3 increase) 0.92 (0.86-0.98) 0.0124
72 hour model (n = 252)
Need for vasoactive treatment 4.43 (1.55-12.68) 0.0055
Platelet count on Day 2-3 (per 10,000 mm-3 increase) 0.92 (0.86-0.99) 0.0331
C-reactive protein (per 1 mg/l increase) on Day 1 1.02 (1.00-1.03) 0.0359
Serum albumin on Day 2-3 (per 1 g/L increase) 0.87 (0.80-0.95) 0.0029
OR - odds ratio; 95% CI - 95% confidence interval; ICU - intensive care unit; WBC - white blood cell count; I/T ratio - immature to total neutrophil 
ratio
Table 5: Diagnostic value of models for prediction of empiric antibiotic treatment failure in neonates.
MLR analysis Classification and regression tree analysis
24 h model 72 h model 24 h model 72 h model
Sensitivity (%) 61 80 75 81
Specificity (%) 90 78 89 88*
Positive predictive value (%) 48 33 46 46
Negative predictive value (%) 94 97 97 97
* difference from MLR model of the same time point significant at p < 0.05
MLR - multiple logistic regressionBMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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of cases change of empirical AB therapy was a clinical deci-
sion, as clinical condition may deteriorate fast but culture
results are often delayed for 36-72 h [9] and many cases of
neonatal sepsis may remain culture negative with present
microbiological methods either due to maternal intrapar-
tum AB exposure [29], low bacterial load or small vol-
umes of blood obtained for culturing [30-32]. Thus, until
better diagnostic tests for neonatal EOS allowing fast dis-
crimination between pathogens, become available for
routine clinical practice [33] there is a need for clinical
parameters to guide the clinician in identifying neonates
at high risk of treatment failure.
One of the main limitations of this study was the use of a
surrogate outcome measure of AB treatment failure. This
was selected because well-defined outcome measures of
EOS, like culture-proven sepsis with AB susceptibility of
causative pathogens and related mortality are extremely
rare, making such outcome based studies hardly manage-
able [6]. Furthermore, with current microbiological meth-
ods, it is likely that many cases of EOS, even those leading
to death will never have positive cultures [29]. Partial
overlap between the study exclusion and AB treatment
change criteria is not surprising, as the clinical conditions
(e.g. meningitis, NEC, septic shock caused by Gram-nega-
tive bacteria resistant to ampicillin etc) prompting these
decisions are likely similar. The difference however, is that
the study entry criteria were evaluated early in life, before
any antibiotics had been given, whereas treatment failure
criteria applied only when antibiotic treatment had been
initiated. To ensure the highest possible specificity we
included autopsy data as still the "golden standard" of
proving clinical infection when bacteriological cultures
remain negative. With this approach 2/3 of treatment fail-
ure cases were based either on positive culture or autopsy
findings and the remaining cases were those that required
wide-spectrum antibiotic therapy for more than 72 hours.
We believe that the three clinically relevant situations
selected by us serve as an adequate marker of ineffective
treatment.
Although there is an identifiable group of high risk
neonates who may benefit from early introduction of AB
treatment with agents of wide spectrum activity this
approach is not problem-free as the use of broad spectrum
antibiotics has been associated with the development and
spread of antibiotic resistance [5]. On the other hand, in
patients with sepsis early appropriate AB coverage may
Decision tree based on data available by 24 h from birth with patient distribution Figure 1
Decision tree based on data available by 24 h from birth with patient distribution. P(TF) - probability of treatment 
failure. For laboratory values the decision algorithm includes the highest and/or lowest values registered within the first 24 h of 
life. Patient groups with P(TF) ≥ 0.3, identified as treatment failures, are surrounded by black box. WBC - white blood cell 
count.
Blood glucose ≥ ≥ 2.55
n=283, P(TF)=0.113
Yes No
Birthweight ≥ ≥ 677.5
n=239, P(TF)=0.075
Yes No
C−reactive protein < < 1.35
n=44, P(TF)=0.318
Yes No
WBC ≥ ≥ 8.25
n=225, P(TF)=0.058
Yes No
n=14
P(TF)=0.357
n=152
P(TF)=0.0197
Platelet count ≥ ≥ 142.5
n=73, P(TF)=0.137
Yes No
n=61
P(TF)=0.082
n=12
P(TF)=0.417
Gestational age ≥ ≥ 27
n=25, P(TF)=0.16
n=18
P(TF)=0
n=7
P(TF)=0.571
Yes No
n=19
P(TF)=0.526BMC Pediatrics 2009, 9:72 http://www.biomedcentral.com/1471-2431/9/72
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outweigh the risks of broad spectrum therapy. Despite
that there are no studies yet, to demonstrate whether this
is true also for neonates, one could speculate that due to
the relative immune suppression and inability to localise
the infection, neonates are even more sensitive to inap-
propriate AB therapy than adults.
Conclusion
In conclusion, post-hoc analysis of a prospective database
identified thrombocytopenia <94.5 × 109 L-1 with con-
comitant need for vasoactive treatment; or WBC below
3.5 × 109 L-1 or above 39.8 × 109 L-1; or blood glucose
below 1.65 mmol/L within 72 h of life; as possible fea-
tures, suggesting the failure of empiric ampicillin plus
gentamicin or penicillin plus gentamicin treatment in sus-
pected EOS. The decision algorithm, as constructed by
CART analysis, needs further validation in prospective
data sets. Whether implementation of broader spectrum
antibiotics, based on these criteria will have any influence
on the outcome of EOS remains to be answered in pro-
spective clinical studies.
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Decision tree based on data available by 72 h from birth with patient distribution Figure 2
Decision tree based on data available by 72 h from birth with patient distribution. P(TF) - probability of treatment 
failure. For laboratory values the decision algorithm includes the highest and/or lowest values registered within the first 72 h of 
life. Patient groups with P(TF) > 0.27, identified as treatment failures, are surrounded by black box. WBC - white blood cell 
count.
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Yes No
Highest WBC< < 39.75
n=237, P(TF)=0.046
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